Creating a favorable market environment by promoting the use of generic and biosimilar medicines
First written in FY2017-Q1. 9 of 10 entries say "Restated". Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1RestatedAnnual report
「In Japan, continued expansion of the market is expected as demand for biosimilars rises further, following measures such as the Ministry of Health, Labour and Welfare setting targets for their adoption and introducing new reimbursement for their use.」
The biosimilar adoption targets and introduction of new reimbursement are being reaffirmed as business conditions that will lead to increased demand and market expansion. - FY2023-Q3RestatedAnnual report
「Against the backdrop of Japan's policy to promote the use of generic drugs to reduce medical costs, we are developing our business so that we can offer patients new treatment options and more affordable treatment.」
The policy to promote the use of generic drugs is being reaffirmed as the market environment for the biosimilar business. - FY2020RestatedAnnual report
「In Japan's pharmaceutical industry, various measures that could transform the industry, including regulatory deregulation and measures to promote the use of generic drugs to reduce social security costs, are beginning to take concrete form alongside the government's growth strategy.」
Changes in the market environment resulting from measures to promote the use of generic drugs and other initiatives are being reaffirmed as business opportunities. - FY2019RestatedAnnual report
「In Japan's pharmaceutical industry, various measures that could transform the industry, including regulatory deregulation and measures to promote the use of generic drugs to reduce social security costs, are beginning to take concrete form alongside the government's growth strategy.」
Changes in the market environment resulting from measures to promote the use of generic drugs and other initiatives continue to be presented as business opportunities. - FY2018RestatedAnnual report
「According to the Basic Policy on Economic and Fiscal Management and Reform 2017, approved by the Cabinet in June 2017, measures to support research and development of biopharmaceuticals and biosimilars are to be expanded, with the aim of doubling the number of biosimilar products by 2020.」
The target of doubling the number of biosimilar products and measures to promote the use of generic drugs are being reaffirmed as favorable business conditions. - FY2018-Q2RestatedAnnual report
「According to the Basic Policy on Economic and Fiscal Management and Reform 2017, approved by the Cabinet in June 2017, measures to support research and development of biopharmaceuticals and biosimilars are to be expanded to contain medical costs, which continue to rise as the population ages, while the number of biosimilar products is to be doubled by the end of fiscal 2020. Measures to promote the use of generic drugs are also being continuously considered and implemented with the aim of raising their usage rate to 80% by September 2020.」
The policy targets of doubling the number of biosimilar products and achieving an 80% usage rate for generic drugs are being reaffirmed as favorable business conditions. - FY2017RestatedAnnual report
「The public and private sectors are working together on measures to contain medical costs and develop the market environment for generic drugs.」
The development of the market environment to contain medical costs and promote the use of generic drugs and biosimilars is being reaffirmed as a favorable business condition. - FY2017-Q3RestatedAnnual report
「As part of these efforts, the development of the market environment to promote the adoption of generic drugs, which are expected to be a key measure for reducing medical costs, continues from various perspectives.」
The market environment continues to be developed to promote the use of generic drugs. - FY2017-Q2RestatedAnnual report
「Reflecting the growing social need, the market environment for promoting the adoption of generic drugs has steadily progressed, including the establishment in April 2016 of the Biosimilar Council to promote and develop biosimilars.」
The Company has reaffirmed its view that the market environment for promoting the adoption of generic drugs and biosimilars is advancing, including through the establishment of the Biosimilar Council. - FY2017-Q1First statedAnnual report
「In the medical and pharmaceutical fields relevant to the Company's business, the Ministry of Health, Labour and Welfare announced in September 2015 its Comprehensive Strategy for Strengthening the Pharmaceutical Industry. The Ministry stated that it would formulate an urgent, intensive and effective strategy aimed at achieving the "80% generic drug era" by simultaneously securing a stable supply of high-quality medicines to the public, improving the efficiency of medical costs and strengthening the industry's competitiveness. In April 2016, the Biosimilar Council was established, led mainly by pharmaceutical companies operating biosimilar businesses in Japan.」
The Company describes the government's target for the adoption of generic drugs, the establishment of the Biosimilar Council, and efforts by academic societies and parliamentary leagues to promote adoption as favourable developments in the market environment for biosimilars.